Cite
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
MLA
Solerte, Sebastiano Bruno, et al. “Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.” Diabetes Care, vol. 43, no. 12, Dec. 2020, pp. 2999–3006. EBSCOhost, https://doi.org/10.2337/dc20-1521.
APA
Solerte, S. B., D’Addio, F., Trevisan, R., Lovati, E., Rossi, A., Pastore, I., Dell’Acqua, M., Ippolito, E., Scaranna, C., Bellante, R., Galliani, S., Dodesini, A. R., Lepore, G., Geni, F., Fiorina, R. M., Catena, E., Corsico, A., Colombo, R., Mirani, M., … Fiorina, P. (2020). Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care, 43(12), 2999–3006. https://doi.org/10.2337/dc20-1521
Chicago
Solerte, Sebastiano Bruno, Francesca D’Addio, Roberto Trevisan, Elisabetta Lovati, Antonio Rossi, Ida Pastore, Marco Dell’Acqua, et al. 2020. “Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.” Diabetes Care 43 (12): 2999–3006. doi:10.2337/dc20-1521.